Lilly will also gain certain rights to MeiraGTx’s proprietary riboswitch technology for use in gene editing in the eye. Under ...

Eli Lilly and Company is making waves across multiple fronts, demonstrating a comprehensive growth strategy that extends well ...

() -MeiraGTx Holdings has signed a deal with Eli Lilly, potentially worth over $475 million,​ granting the pharma giant ...

MeiraGTx will receive an upfront payment of $75 million and will be eligible to receive over $400 million in total milestone ...

MeiraGTx (MGTX) shares added ~18% in the premarket on Monday after the genetic medicines company announced a broad strategic ...

MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic collaboration in the area of ophthalmology with Eli Lilly and ...

Eli Lilly is partnering with MeiraGTx to develop and commercialize ophthalmology gene therapies, and with SanegeneBio to ...

Eli Lilly’s fair value estimate has recently been raised from $891.62 to $919.33. This reflects a modest increase in the company’s intrinsic valuation amid evolving market sentiment. The upward ...

Eli Lilly will partner with Insilico Medicine on an artificial intelligence (AI)-based drug development collaboration that they said could generate “over $100 million” for the AI drug discovery ...

MeiraGTx shares rise after signing a $475 million deal with Eli Lilly for a gene therapy program restoring vision in children ...

Two Texas compounding pharmacies are the latest to get sued in Eli Lilly’s multistate battle to stop sales of replica ...

MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic collaboration in ...